Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Experimental and Clinical Virology ; (6): 36-38, 2008.
Artigo em Chinês | WPRIM | ID: wpr-254148

RESUMO

<p><b>OBJECTIVE</b>To investigate the relationship between the genetic polymorphisms of CYP3A5 and the clinical effectiveness of Bicyclol on patients with chronic hepatitis B to make individual medication possible.</p><p><b>METHODS</b>34 cases of chronic hepatitis B were treated by bicyclol tablets for 24 weeks. Liver function indexes (ALT and AST) were determined before and after treatment. Blood CYP3A5 genotyping of each patient was determined by the PCR-RFLP analysis.</p><p><b>RESULTS</b>All subjects were genotyped for the CYP3A5*3 gene and divided into different group. The groups comprised subjects with CYP3A5*3 carriers (n=18) and CYP3A5*1 carriers (n=16) which include CYP3A5*1/*1 (n=2) and CYP3A5*1/*3 (n=14). Compared with pre-treatment, the serum ALT and AST levels were decreased obviously in all patients. The mean percentage reduction of serum ALT and AST levels were significantly greater in subjects with CYP3A5*3 carriers (79.73% and 74.76%) than in those with CYP3A5*1 carriers (65.90% and 49.63%; P < 0.05) The recovery rates of ALT and AST were significantly highter in CYP3A5*3 carriers than those in CYP3A5*1 carriers (P < 0.05).</p><p><b>CONCLUSION</b>CYP3A5 genotype has an impact on the therapeutic effects of Bicyclol. The subjects with CYP3A5*3 carriers is more effective than the subjects with CYP3A5*1 carriers. CYP3A5 genotyping may be helpful in predicting therapeutic effects of Bicyclol especially in the terms of decreasing ALT and AST.</p>


Assuntos
Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Alanina Transaminase , Sangue , Compostos de Bifenilo , Farmacologia , Usos Terapêuticos , Citocromo P-450 CYP3A , Genética , Genótipo , Hepatite B Crônica , Sangue , Tratamento Farmacológico , Genética , Fígado , Polimorfismo Genético
2.
China Journal of Chinese Materia Medica ; (24): 358-361, 2003.
Artigo em Chinês | WPRIM | ID: wpr-272854

RESUMO

<p><b>OBJECTIVE</b>To determine the effects of Varglaucocalyx on c-fos gene expression during global myocardial ischemia-reperfusion.</p><p><b>METHOD</b>Forty Wistar rats were divided into 5 groups: group N as control; group CN as ischemia-reperfusion control and group XH, XM and XL treated with Varglaucocalyx 5%, 1%, 0.5% respectively prior to ischemia-reperfusion. The isolated rat hearts were perfused in condition of constant temperature and pressure, and then the left ventricular myocardiums were extracted for use. The expression of c-fos protein was detected by immunochemical method. The expression of c-fos protein were quantified by using computer image analysis system.</p><p><b>RESULT</b>Compared with the values of group N, protein expressions relative area of c-fos gene (PERA) were increased significantly in group CN, XH, XM, XL(P < 0.01), but decreased significantly in group XH, XM, XL, compared with those of group CN (P < 0.05). The PERA of c-fos gene in group XM, XL were significantly lower than in group XH (P < 0.01), and the PERA of c-fos gene in group XM were lower than in group XL(P < 0.05).</p><p><b>CONCLUSION</b>Varglaucocalyx can effectively depress the expression of c-fos gene in myocardium which may account for its protection against myocardial ischemia-reperfusion injury, and the middle and the low concentrations of Varglaucocalyx are more effective than the high concentrations.</p>


Assuntos
Animais , Feminino , Masculino , Ratos , Cardiotônicos , Farmacologia , Medicamentos de Ervas Chinesas , Farmacologia , Regulação da Expressão Gênica , Genes fos , Isodon , Química , Traumatismo por Reperfusão Miocárdica , Metabolismo , Miocárdio , Metabolismo , Plantas Medicinais , Química , Proteínas Proto-Oncogênicas c-fos , Distribuição Aleatória , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA